HDACs/EZH2-IN-1

HDACs/EZH2-IN-1

• UNSPSC Description: HDACs/EZH2-IN-1 (Compound 22a) is a HDACs/EZH2 inhibitor (EZH2 Y641N inhibition rate at 50 nM: 98%), with selective inhibition against HDAC1 and HDAC6 (IC50: 0.23 μM and 0.07 μM, respectively). HDACs/EZH2-IN-1 exerts a antiproliferative effect on diffuse large B-cell lymphoma cells harboring an EZH2 mutation and on various acute myeloid leukemia cells. HDACs/EZH2-IN-1 has the ability to induce cell differentiation and Apoptosis[1].
• Target Antigen: Apoptosis; HDAC; Histone Methyltransferase
• Type: Reference compound
• Related Pathways: Apoptosis;Cell Cycle/DNA Damage;Epigenetics
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/hdacs-ezh2-in-1.html
• Smiles: BrC1=CC(N(CC2CCN(CC2)C3=NC=C(C=N3)C(NO)=O)CC)=C(C(C(NCC4=C(C=C(NC4=O)C)C)=O)=C1)C
• Molecular Weight: 626.54
• References & Citations: [1]Zhang J, et al. Discovery of epigenetic modulators targeting HDACs and EZH2 simultaneously for the treatment of hematological malignancies. Bioorganic chemistry, 2024, 153, 107964.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported